Feb 2 |
Protagonist (PTGX) Up 14% on Licensing Deal With Takeda
|
Feb 1 |
Protagonist Therapeutics stock rises on Takeda license deal
|
Feb 1 |
Takeda pays $300M to license Protagonist drug for blood disorder
|
Jan 31 |
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
|
Jan 29 |
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
|
Jan 12 |
Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX)
|
Jan 3 |
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
|
Dec 31 |
A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
|
Dec 16 |
Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...
|
Dec 13 |
Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
|